BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32872735)

  • 1. Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors.
    Choi J; Oh JY; Lee YS; Min KH; Shim JJ; Choi SI; Park DW; Park CK; Kang EJ; Yong HS; Shin BK; Kim HK; Lee SY
    Korean J Intern Med; 2022 Jan; 37(1):127-136. PubMed ID: 32872735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of adjuvant chemotherapy on patients with stage IB non-small cell lung cancer with visceral pleural invasion.
    Kim BG; Choi J; Lee SK; Choi SI; Park CK; Sim JK; Lee H; Kim SH; Sohn JW; Yoon HJ; Lee SY; Park DW
    J Thorac Dis; 2024 Feb; 16(2):875-883. PubMed ID: 38505035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non-small cell lung cancer.
    Zhang P; Duan J; Bai H; Wang Z; Gao S; Tan F; Gao Y; Wang X; Wan R; Xu J; He X; Feng X; Yu R; Sun J; Zhao Z; Fei K; Li N; He J; Wang J
    Thorac Cancer; 2021 Jan; 12(1):30-39. PubMed ID: 33111432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion.
    Xie J; Zhang X; Hu S; Peng WD; Xu B; Li Y; Zhang SJ; Li Q; Li C
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2231-2239. PubMed ID: 32533405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification.
    Maeda R; Yoshida J; Ishii G; Hishida T; Nishimura M; Nagai K
    Chest; 2011 Dec; 140(6):1494-1502. PubMed ID: 21622548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.
    Pathak R; Goldberg SB; Canavan M; Herrin J; Hoag JR; Salazar MC; Papageorge M; Ermer T; Boffa DJ
    JAMA Oncol; 2020 Nov; 6(11):1741-1750. PubMed ID: 32940636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database.
    De Giglio A; Di Federico A; Gelsomino F; Ardizzoni A
    Lung Cancer; 2021 Nov; 161():18-25. PubMed ID: 34492552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer.
    Park SY; Lee JG; Kim J; Byun GE; Bae MK; Lee CY; Kim DJ; Chung KY
    J Cardiothorac Surg; 2013 Jun; 8():151. PubMed ID: 23759129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic invasion is a more significant prognostic factor than visceral pleural invasion in non-small cell lung cancer with tumours of 3 cm or less.
    Moon Y; Park JK; Lee KY; Sung SW
    Respirology; 2017 Aug; 22(6):1179-1184. PubMed ID: 28382791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a low risk subgroup of stage IB lung adenocarcinoma patients.
    Mizuno T; Ishii G; Nagai K; Yoshida J; Nishimura M; Mochizuki T; Kawai O; Hasebe T; Ochiai A
    Lung Cancer; 2008 Dec; 62(3):302-8. PubMed ID: 18486987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences.
    Oven Ustaalioglu BB; Unal OU; Turan N; Bilici A; Kaya S; Eren T; Ulas A; Inal A; Berk V; Demirci U; Alici S; Bal O; Benekli M; Gumus M
    Asian Pac J Cancer Prev; 2013; 14(11):6287-92. PubMed ID: 24377519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor prognostic factors in patients with stage IB non-small cell lung cancer according to the seventh edition TNM classification.
    Maeda R; Yoshida J; Ishii G; Hishida T; Nishimura M; Nagai K
    Chest; 2011 Apr; 139(4):855-861. PubMed ID: 20724736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multivariate survival analysis of patients with stage I NSCLC].
    Pei J; Han B; Zhang J; Gu A
    Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):926-32. PubMed ID: 22152692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study.
    Ak N; Ozkan B; Yenigun MB; Yilmazbayhan D; Toker A; Ferhatoglu F; Yasar A; Dizbay Sak S; Tanju S; Dilege S; Erus S; Bulutay P; Firat P; Molinas Mandel N; Kilickap S; Onder S; Dikmen E; Alan O; Yumuk PF; Bozkurtlar E; Lacin T; Yildizeli B; Ozturk A; Kocaturk C; Karapinar K; Urer N; Oyan B; Aydiner A; Demirkazik A; Eralp Y
    J BUON; 2021; 26(3):819-829. PubMed ID: 34268941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer.
    Noma D; Inamura K; Matsuura Y; Hirata Y; Nakajima T; Yamazaki H; Hirai Y; Ichinose J; Nakao M; Ninomiya H; Mun M; Nakagawa K; Masuda M; Ishikawa Y; Okumura S
    Clin Lung Cancer; 2018 Jan; 19(1):e109-e122. PubMed ID: 29066222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor.
    Manac'h D; Riquet M; Medioni J; Le Pimpec-Barthes F; Dujon A; Danel C
    Ann Thorac Surg; 2001 Apr; 71(4):1088-93. PubMed ID: 11308141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy for visceral pleural invasion in 3-4-cm non-small-cell lung cancer improves survival.
    Wightman SC; Lee JY; Ding L; Atay SM; Shemanski KA; McFadden PM; David EA; Kim AW
    Eur J Cardiothorac Surg; 2022 Jun; 62(1):. PubMed ID: 35325098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.